[Myasthenia gravis; clinical aspects, pathophysiology and treatment].
D001323:Autoantibodies; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009157:Myasthenia Gravis / Q000276:immunology / Q000503:physiopathology* / Q000628:therapy; D009469:Neuromuscular Junction / Q000503:physiopathology; D010353:Patient Education as Topic; D010956:Plasmapheresis; D011950:Receptors, Cholinergic / Q000276:immunology*; D009435:Synaptic Transmission; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D013934:Thymectomy; D013945:Thymoma / Q000503:physiopathology; D013953:Thymus Neoplasms / Q000503:physiopathology
D001323:Autoantibodies; D002800:Cholinesterase Inhibitors; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic
Myasthenia gravis; klinisch beeld, pathofysiologie en behandeling.